60 related articles for article (PubMed ID: 14630508)
1. Clinical feasibility study of early 30-minute dynamic FDG-PET scanning protocol for patients with lung lesions.
Du F; Wumener X; Zhang Y; Zhang M; Zhao J; Zhou J; Li Y; Huang B; Wu R; Xia Z; Yao Z; Sun T; Liang Y
EJNMMI Phys; 2024 Mar; 11(1):23. PubMed ID: 38441830
[TBL] [Abstract][Full Text] [Related]
2. Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions?
Skawran S; Messerli M; Kotasidis F; Trinckauf J; Weyermann C; Kudura K; Ferraro DA; Pitteloud J; Treyer V; Maurer A; Huellner MW; Burger IA
Life (Basel); 2022 Aug; 12(9):. PubMed ID: 36143386
[TBL] [Abstract][Full Text] [Related]
3. Short 2-[
Indovina L; Scolozzi V; Capotosti A; Sestini S; Taralli S; Cusumano D; Giancipoli RG; Ciasca G; Cardillo G; Calcagni ML
Front Med (Lausanne); 2021; 8():725387. PubMed ID: 34881253
[No Abstract] [Full Text] [Related]
4. Analysis of Four-Dimensional Data for Total Body PET Imaging.
Viswanath V; Chitalia R; Pantel AR; Karp JS; Mankoff DA
PET Clin; 2021 Jan; 16(1):55-64. PubMed ID: 33218604
[TBL] [Abstract][Full Text] [Related]
5. Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials.
Doot RK; McDonald ES; Mankoff DA
Clin Transl Imaging; 2014 Aug; 2(4):295-303. PubMed ID: 25229053
[TBL] [Abstract][Full Text] [Related]
6. Multivariate analysis of various factors affecting background liver and mediastinal standardized uptake values.
Kuruva M; Mittal BR; Abrar ML; Kashyap R; Bhattacharya A
Indian J Nucl Med; 2012 Jan; 27(1):20-3. PubMed ID: 23599593
[TBL] [Abstract][Full Text] [Related]
7. Exploring temporospatial changes in glucose metabolic disorder, learning, and memory dysfunction in a rat model of diffuse axonal injury.
Li J; Gu L; Feng DF; Ding F; Zhu G; Rong J
J Neurotrauma; 2012 Nov; 29(17):2635-46. PubMed ID: 22880625
[TBL] [Abstract][Full Text] [Related]
8. Multi-observation PET image analysis for patient follow-up quantitation and therapy assessment.
David S; Visvikis D; Roux C; Hatt M
Phys Med Biol; 2011 Sep; 56(18):5771-88. PubMed ID: 21846937
[TBL] [Abstract][Full Text] [Related]
9. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Dunnwald LK; Doot RK; Specht JM; Gralow JR; Ellis GK; Livingston RB; Linden HM; Gadi VK; Kurland BF; Schubert EK; Muzi M; Mankoff DA
Clin Cancer Res; 2011 Apr; 17(8):2400-9. PubMed ID: 21364034
[TBL] [Abstract][Full Text] [Related]
10. Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis.
Cheebsumon P; Velasquez LM; Hoekstra CJ; Hayes W; Kloet RW; Hoetjes NJ; Smit EF; Hoekstra OS; Lammertsma AA; Boellaard R
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):832-42. PubMed ID: 21210109
[TBL] [Abstract][Full Text] [Related]
11. Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET.
Honer M; Ebenhan T; Allegrini PR; Ametamey SM; Becquet M; Cannet C; Lane HA; O'Reilly TM; Schubiger PA; Sticker-Jantscheff M; Stumm M; McSheehy PM
Transl Oncol; 2010 Aug; 3(4):264-75. PubMed ID: 20689768
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging as a tool for translating breast cancer science.
Mankoff DA
Breast Cancer Res; 2008; 10 Suppl 1(Suppl 1):S3. PubMed ID: 19091007
[TBL] [Abstract][Full Text] [Related]
13. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
[TBL] [Abstract][Full Text] [Related]
14. Current and future use of positron emission tomography (PET) in breast cancer.
Mankoff DA; Eubank WB
J Mammary Gland Biol Neoplasia; 2006 Apr; 11(2):125-36. PubMed ID: 17075687
[TBL] [Abstract][Full Text] [Related]
15. Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method?
Mankoff DA; Muzi M; Krohn KA
Mol Imaging Biol; 2003; 5(5):281-5. PubMed ID: 14630508
[No Abstract] [Full Text] [Related]
16. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.
Rigo P; Paulus P; Kaschten BJ; Hustinx R; Bury T; Jerusalem G; Benoit T; Foidart-Willems J
Eur J Nucl Med; 1996 Dec; 23(12):1641-74. PubMed ID: 8929320
[TBL] [Abstract][Full Text] [Related]
17. Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future.
Minn H; Paul R
Eur J Nucl Med; 1992; 19(11):921-4. PubMed ID: 1425778
[No Abstract] [Full Text] [Related]
18. PET quantitation: blessing and curse.
Di Chiro G; Brooks RA
J Nucl Med; 1988 Sep; 29(9):1603-4. PubMed ID: 3261788
[No Abstract] [Full Text] [Related]
19. Positron emission tomographic oncology.
Lawson MA
West J Med; 1994 Oct; 161(4):411-2. PubMed ID: 7817554
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
